Ascentage Pharma Group International (AAPG) Common Equity (2022 - 2024)

Historic Common Equity for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q4 2024 value amounting to $38.2 million.

  • Ascentage Pharma Group International's Common Equity rose 28907.3% to $38.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $38.2 million, marking a year-over-year increase of 28907.3%. This contributed to the annual value of $37.6 million for FY2024, which is 27580.32% up from last year.
  • Latest data reveals that Ascentage Pharma Group International reported Common Equity of $38.2 million as of Q4 2024, which was up 28907.3% from $9.8 million recorded in Q4 2023.
  • Over the past 5 years, Ascentage Pharma Group International's Common Equity peaked at $57.5 million during Q4 2022, and registered a low of $9.8 million during Q4 2023.
  • Moreover, its 3-year median value for Common Equity was $38.2 million (2024), whereas its average is $35.1 million.
  • In the last 5 years, Ascentage Pharma Group International's Common Equity tumbled by 8292.71% in 2023 and then soared by 28907.3% in 2024.
  • Quarter analysis of 3 years shows Ascentage Pharma Group International's Common Equity stood at $57.5 million in 2022, then crashed by 82.93% to $9.8 million in 2023, then soared by 289.07% to $38.2 million in 2024.
  • Its Common Equity stands at $38.2 million for Q4 2024, versus $9.8 million for Q4 2023 and $57.5 million for Q4 2022.